Evidence map›Paper›PMID 26683181›Full record

ArticleMonoclonal antibodies in immunodiagnosis and immunotherapy2015

Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor.

Tomohiro Osaki, Cai-Xia Wang, Taro Tachibana, Masayuki Azuma, Masaya Kitamura, Takeshi Nakanishi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Monoclonal antibodies in immunodiagnosis and immunotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomohiro Osaki1 Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka City University , Sumiyoshi-ku, Osaka, Japan .
Cai-Xia Wang1 Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka City University , Sumiyoshi-ku, Osaka, Japan .
Taro Tachibana1 Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka City University , Sumiyoshi-ku, Osaka, Japan .
Masayuki Azuma1 Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka City University , Sumiyoshi-ku, Osaka, Japan .
Masaya Kitamura1 Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka City University , Sumiyoshi-ku, Osaka, Japan .
Takeshi Nakanishi1 Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka City University , Sumiyoshi-ku, Osaka, Japan .

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overexpression of the epidermal growth factor receptor (EGFR) gene and dysregulation of EGFR signaling are observed in various cancer cells, and EGFR is a validated target for cancer therapy. In the present study, we report on the generation of two rat anti-EGFR antibodies (clones 2C2D3 and 4H7F4) by using the rat lymph node method. Flow cytometric analysis and immunofluorescence showed that both antibodies specifically bound to EGFR on the surface of cancer cells. Competitive analysis demonstrated that the epitope of each antibody had no overlap with that of the therapeutic anti-EGFR antibody cetuximab. These results suggest that 2C2D3 and 4H7F4 are potentially useful in EGFR-targeted cancer therapy.

Indexed as

AnimalsAntibodies, MonoclonalAntibody SpecificityCell FusionCell Line, TumorEnzyme-Linked Immunosorbent AssayEpitopesErbB ReceptorsFemaleGene ExpressionHEK293 CellsHumansHybridomasLymph NodesLymphocytesMiceAntibodies, MonoclonalEGFR protein, humanEpitopesErbB ReceptorsPeptides

Identifiers

PMID26683181
PMCPMC4685498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.